Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 2014

View Archived Issues

First-in-class BRD2/3/4 inhibitor OTX-015, a potential broad-spectrum anticancer drug

Novel biomarker described for Alzheimer's disease

Ono and Gilead to collaborate on global development of BTK inhibitor

First-in-class P2X3 receptor AF-219 evaluated in refractory cough

An2-conjugated anti-HER2 MAb and MAb-drug conjugates designed to cross BBB

Dr. Reddy's completes acquisition of Habitrol

Rights to anticancer drug AUY-922 revert to Vernalis

Keryx Biopharmaceuticals launches Auryxia in the U.S.

FDA grants orphan drug designation to Nuvilex treatment for pancreatic cancer

C&C Research Laboratories patent details novel STAT3 inhibitors

Merck & Co. reports CYP3A4 inhibitors to improve PK of anti-HIV drugs

Evestra reports progesterone antagonists for breast cancer

Lupin patent divulges a novel nAChR PAM

Galapagos begins first phase I study in cystic fibrosis

Approved drug CB-008 inhibits Ebola virus in vitro

Radius Health reports phase III topline results for abaloparatide-SC

INTERCEPT Blood System receives FDA approvals and meets phase II study endpoints

Travoprost approved in the E.U. for pediatric glaucoma

Chugai seeks Japanese approval of Xeloda as postoperative adjuvant chemotherapy for gastric cancer

EMA committee recommends approval of dalbavancin

E.U. marketing approval granted for Duavive for postmenopausal estrogen deficiency symptoms

Actelion files NDA for selexipag in pulmonary arterial hypertension

Medivir selects MIV-802 as drug candidate for treatment of HCV infection

Celgene receives positive CHMP opinion to extend Revlimid indication

FDA approves Soolantra for the once-daily treatment of inflammatory lesions in rosacea

Liraglutide approved in U.S. for weight loss

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...